David Miklos

4.8/5

Biography

I am the Chief of Stanford BMT and Cell Therapy Program that provides 750 cancer cell therapies annually. Our BMT-CT research fosters the development of both laboratory immunologists, and clinical translational researchers. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cures blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. Our goal is to combine graft engineered allogeneic HCT with CAR-T benefit.

The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. More recently, our team developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, flow cytometry tumor antigen quantification, Immune phenotype CAR-T characterization (CAR-FACS), and single cell RNA characterization of CAR-T cells.

Immunotherapy is revolutionizing cancer treatment and Stanford Cancer Cell Therapy Program is developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD20, CD22, CD79A, and BCMA.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Hematology (2002)
Board Certification, American Board of Internal Medicine, Hematology (2019)
Medical Education: Yale University Office of the Registrar (1995) CT

Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2001) MA

Residency: Brigham and Women's Hospital Harvard Medical School (1998) MA

Internship: Brigham and Women's Hospital Harvard Medical School (1996) MA

B.S., University of Notre Dame (1987)

M.D., Yale University Medical School (1995)

Ph.D., Yale University, Genetics (1995)

Honors & Awards

Alpha Omega Alpha, Yale Medical School (1995)
Clinical Investigator Training Program Scholar, Harvard Medical School (2001-2003)
Medical Scientist Training Fellow, NIH (1993-1995)

Phi Betta Kappa, University of Notre Dame (1987)

Predoctoral Fellow, Howard Hughes Medical Institute (1989-1993)

Memberships

Member, American Society of Transplantation and Cell Therapy (1998 - Present)
Member, American Society of Clinical Oncology (2014 - Present)
Member, American Society of Hematology (1998 - Present)

Administrative Appointments

Associate Chief Blood and Marrow Transplantation, Stanford University (2020 - 2020)
Chief BMT and Cell Therapy Program, Stanford University (2020 - Present)
Clinical Director Cancer Cell Therapy, Stanford University (2016 - 2022)

Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford University (2011 - 2016)

Publications

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. X., Mattes-Ritz, A., … Ritz, J. (2004). Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. BLOOD, 103(1), 353–359.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L. X., Zorn, E., Lee, S. J., … Ritz, J. (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. BLOOD, 105(7), 2973–2978.
Renal pathology in hematopoietic cell transplantation recipients
Troxell, M. L., Pilapil, M., Miklos, D. B., Higgins, J. P., & Kambham, N. (2008). Renal pathology in hematopoietic cell transplantation recipients. MODERN PATHOLOGY, 21(4), 396–406.

H-Y antibody development associates with acute rejection in female patients with male kidney transplants
Tan, J. C., Wadia, P. P., Coram, M., Grumet, F. C., Kambham, N., Miller, K., … Miklos, D. B. (2008). H-Y antibody development associates with acute rejection in female patients with male kidney transplants. TRANSPLANTATION, 86(1), 75–81.

Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures
Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., Sigdel, T. K., … Butte, A. J. (2009). Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4148–53.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109.

Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation
Wadia, P. P., Coram, M., Armstrong, R. J., Mindrinos, M., Butte, A. J., & Miklos, D. B. (2010). Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. BLOOD, 115(10), 2077–87.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54.

Rituximab in hematopoietic cell transplantation
Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971–82.

Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements
Boyd, S. D., Gaeta, B. A., Jackson, K. J., Fire, A. Z., Marshall, E. L., Merker, J. D., … Collins, A. M. (2010). Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements. JOURNAL OF IMMUNOLOGY, 184(12), 6986–92.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99.

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637–39.

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
Müller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721–26.

Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease
Butte, A. J., Sigdel, T. K., Wadia, P. P., Miklos, D. B., & Sarwal, M. M. (2011). Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease. MOLECULAR & CELLULAR PROTEOMICS, 10(3).

Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL
Tseng, D., Jones, C. D., Anderson, M., Warnke, R., Zehnder, J. L., & Miklos, D. B. (2011). Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. BONE MARROW TRANSPLANTATION, 46(12), 1576–78.

Recombinant antigen microarrays for serum/plasma antibody detection.
Wadia, P. P., Sahaf, B., & Miklos, D. B. (2011). Recombinant antigen microarrays for serum/plasma antibody detection. Methods in Molecular Biology (Clifton, N.J.), 723, 81–104.

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., … Engleman, E. G. (2011). B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. NATURE MEDICINE, 17(5), 610–U134.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87.

Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation
Porcheray, F., Miklos, D. B., Floyd, B. H., Sarantopoulos, S., Bellucci, R., Soiffer, R. J., … Zorn, E. (2011). Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. TRANSPLANTATION, 92(3), 359–65.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78.

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
Logan, A. C., Gao, H., Wang, C., Sahaf, B., Jones, C. D., Marshall, E. L., … Miklos, D. B. (2011). High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(52), 21194–99.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54.

Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
Logan, A. C., Zhang, B., Narasimhan, B., Carlton, V., Zheng, J., Moorhead, M., … Miklos, D. B. (2013). Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. LEUKEMIA, 27(8), 1659–65.

A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.
Meyer, E. H., Hsu, A. R., Liliental, J., Löhr, A., Florek, M., Zehnder, J. L., … Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood, 121(24), 4955–62.

The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age
Dong, L., Wu, T., Gao, Z.-Y., Zhang, M.-J., Kan, F., Spellman, S. R., … Lee, S. J. (2011). The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1205–13.

Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation
Dobbelstein, C., Ahn, K. W., Haagenson, M., Hale, G. A., Van Rood, J. J., Miklos, D., … Lee, S. J. (2013). Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(5), 741–45.

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report
Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., … Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126–37.

Rituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., … Alyea, E. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. BLOOD. KEYSTONE,CO,CO,CO,CO,CO,CO,CO: AMER SOC HEMATOLOGY.

H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births
Nielsen, H. S., Wu, F., Aghai, Z., Steffensen, R., van Halteren, A. G., Spierings, E., … Goulmy, E. (2010). H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. HUMAN REPRODUCTION, 25(11), 2745–2752.

Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease
Namboodiri, A. M., Nietert, P. J., Wadia, P. P., Miklos, D. B., & Pandey, J. P. (2012). Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease. VIRAL IMMUNOLOGY, 25(4), 338–340.

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
Shaw, P. J., Kan, F., Ahn, K. W., Spellman, S. R., Aljurf, M., Ayas, M., … Pulsipher, M. A. (2010). Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. BLOOD, 116(19), 4007–15.

B Cells and Transplantation: An Educational Resource
Small, T. N., Robinson, W. H., & Miklos, D. B. (2009). B Cells and Transplantation: An Educational Resource. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(1), 104–13.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43.

Clinical impact of H-Y alloimmunity.
Popli, R., Sahaf, B., Nakasone, H., Lee, J. Y. Y., & Miklos, D. B. (2014). Clinical impact of H-Y alloimmunity. Immunologic Research, 58(2-3), 249–58.

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan, A. C., Vashi, N., Faham, M., Carlton, V., Kong, K., Buño, I., … Miklos, D. B. (2014). Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biology of Blood and Marrow Transplantation , 20(9), 1307–13.

Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.
Fleischhauer, K., Fernandez-Viña, M. A., Wang, T., Haagenson, M., Battiwalla, M., Baxter-Lowe, L. A., … Spellman, S. R. (2014). Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone Marrow Transplantation, 49(9), 1176–83.

A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor.
Mahadeo, K. M., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Killen, R., Kohn, D., … Kapoor, N. (2015). A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. Biology of Blood and Marrow Transplantation , 21(3), 440–44.

Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
Nakasone, H., Tian, L., Sahaf, B., Kawase, T., Schoenrock, K., Perloff, S., … Miklos, D. B. (2015). Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. BLOOD, 125(20), 3193–3201.

ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation
Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., Negrin, R. S., … Miklos, D. B. (2015). ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(4), 746–54.

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–87.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation.

Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
Nakasone, H., Sahaf, B., & Miklos, D. B. (2015). Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. INTERNATIONAL JOURNAL OF HEMATOLOGY, 101(5), 438–51.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report
Paczesny, S., Hakim, F. T., Pidala, J., Cooke, K. R., Lathrop, J., Griffith, L. M., … Schultz, K. R. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(5), 780–92.

Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.
Nickel, R. S., Hendrickson, J. E., Yee, M. M., Bray, R. A., Gebel, H. M., Kean, L. S., … Horan, J. T. (2015). Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. British Journal of Haematology, 170(2), 247–56.

Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., … Meyer, E. (2015). Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica, 100(11), 1477–85.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92.

A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease
Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., Zehnder, J. L., … Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. BLOOD, 121(24), 4955–62.

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation
Mueller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(33), 14721–26.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood.

The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.
Cooke, K. R., Luznik, L., Sarantopoulos, S., Hakim, F. T., Jagasia, M., Fowler, D. H., … Blazar, B. R. (2016). The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation .

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., … Miklos, D. B. (2018). Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(2), 373–80.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., … Jaglowski, S. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. BLOOD, 130(21), 2243–50.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2018). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. Leukemia & Lymphoma, 1–4.

Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes
Nakasone, H., Sahaf, B., Tian, L., Wang, T., Haagenson, M. D., Schoenrock, K., … Miklos, D. B. (2016). Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. HAEMATOLOGICA, 101(1), E30–E33.

Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
Locke, F. L., Ghobadi, A., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Jacobsen, E., … Neelapu, S. S. (2018). Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18, S276.

Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
Locke, F. L., Ghobadi, A., Jacobson, C. A., Jacobsen, E., Miklos, D. B., Lekakis, L. J., … Neelapu, S. S. (2018). Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18, S277–S278.

Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies
Miklos, D., Muffly, L., Lee, L. W., & Crossley, B. (2018). Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18, S295–S296.

Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease.
Paz, K., Flynn, R., Du, J., Qi, J., Luznik, L., Maillard, I., … Blazar, B. (2018). Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease. Blood.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., … Neelapu, S. S. (2018). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet. Oncology.

A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation.
Paul, J., Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., … Miklos, D. (2019). A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica.

Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD. AMER SOC HEMATOLOGY.

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy
Oak, J., Spiegel, J. Y., Sahaf, B., Natkunam, Y., Long, S. R., Hossain, N., … Miklos, D. B. (2018). Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. BLOOD. AMER SOC HEMATOLOGY.

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, C. A., Locke, F. L., Miklos, D. B., Herrera, A. F., Westin, J. R., Lee, J., … Sun, J. (2018). End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, S. S., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., … Locke, F. L. (2018). 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
Hossain, N., Sahaf, B., Abramian, M., Spiegel, J. Y., Kong, K., Kim, S., … Miklos, D. B. (2018). Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. BLOOD. AMER SOC HEMATOLOGY.

1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A. C., Mavroukakis, S., … Mackall, C. L. (2018). 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). BLOOD. AMER SOC HEMATOLOGY.

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Nastoupil, L. J., Jain, M. D., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., … Locke, F. L. (2018). Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. BLOOD. AMER SOC HEMATOLOGY.

Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1
Rossi, J. M., Galon, J., Turcan, S., Danan, C., Locke, F. L., Neelapu, S. S., … Bot, A. (2018). Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1. CANCER RESEARCH, 78(13).

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Waller, E. K., Miklos, D., Cutler, C., Arora, M., Jagasia, M. H., Pusic, I., … Jaglowski, S. (2019). Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.

Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., … Lin, Y. (2019). Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.
Thangavelu, G., Du, J., Paz, K. G., Loschi, M., Zaiken, M. C., Flynn, R., … Blazar, B. R. (2019). Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease. Blood.

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., … Alizadeh, A. A. (2019). Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., … Reagan, P. M. (2020). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P. M., Miklos, D. B., … Gisselbrecht, C. (2020). A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu, S. S., Jacobson, C. A., Oluwole, O. O., Munoz, J., Deol, A., Miklos, D., … Locke, F. L. (2020). Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., … Reagan, P. M. (2020). KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England Journal of Medicine, 382(14), 1331–42.

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., … Locke, F. L. (2020). Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1902104.

A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P., Miklos, D. B., … Gisselbrecht, C. (2020). A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL). MOLECULAR THERAPY. CELL PRESS.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., … Neelapu, S. S. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. LANCET ONCOLOGY, 20(1), 31–42.

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9).

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., … Bot, A. (2020). Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 4(19), 4898–4911.

Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
Alam*, I. S., & Simonetta*, F. (2020). Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 1058–68.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.
Spiegel, J. Y., Dahiya, S., Jain, M. D., Tamaresis, J. S., Nastoupil, L., Jacobs, M. T., … Miklos, D. B. (2020). Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood.

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2
Wang, M., Munoz, J., Goy, A., Locke, F., Jacobson, C., Hill, B., … Reagan, P. (2020). KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155.

Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Reveron-Thornton, R., Scott, B. J., Post, D., Finley Caulfield, A., Werbaneth, K., Hovsepian, D. A., … Patel, C. B. (2021). Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. The Neurohospitalist, 74–79.

Updated Results of a Phase 1b/2 Study of Ibrutinib in Chronic Graft Versus Host Disease After Failure of Prior Therapy
Waller, E. K., Miklos, D., Cutler, C. S., Arora, M., Jagasia, M., Pusic, I., … Jaglowski, S. (2018). Updated Results of a Phase 1b/2 Study of Ibrutinib in Chronic Graft Versus Host Disease After Failure of Prior Therapy. BONE MARROW TRANSPLANTATION, 53, 71–73.

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2019). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. LEUKEMIA & LYMPHOMA, 60(2), 503–506.

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., … Neelapu, S. S. (2021). CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood.

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., … Miklos, D. B. (2021). Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2100377.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine.

Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.
Tees, M. T., Neelapu, S. S., Hari, P., Mailankody, S., Miklos, D. B., Locke, F. L., … Wang, E. (2021). Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).
Jacobson, C. A., Locke, F. L., Hu, Z.-H., Siddiqi, T., Ahmed, S., Ghobadi, A., … Pasquini, M. C. (2021). Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., … Westin, J. R. (2021). Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. The New England Journal of Medicine.

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., … Galon, J. (2022). Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nature Medicine.

Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., … Mackall, C. L. (2022). Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy. NATURE MEDICINE.

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., … Alizadeh, A. A. (2022). Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell.

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos, D. B., Abu Zaid, M., Cooney, J. P., Albring, J. C., Flowers, M., Skarbnik, A. P., … Socie, G. (2023). Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2200509.

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., … Jain, M. D. (2023). Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201797.

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).
Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., … Locke, F. L. (2023). 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood.

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood.

PROTEOMIC PROFILING IN BLOOD IDENTIFIES NOVEL PRETREATMENT AND MECHANISTIC MARKERS RELATED TO INFLAMMATORY ADVERSE EVENTS IN RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER AXICABTAGENE CILOLEUCEL
Speth, K., Tiwari, G., Adhikary, S., Song, Q., Chou, J., Locke, F., … Bot, A. (2022). PROTEOMIC PROFILING IN BLOOD IDENTIFIES NOVEL PRETREATMENT AND MECHANISTIC MARKERS RELATED TO INFLAMMATORY ADVERSE EVENTS IN RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER AXICABTAGENE CILOLEUCEL. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.

MULTIOMICS AND MULTIMODAL ANALYSIS APPROACH TO CONSTRUCT A DIFFUSE LARGE B CELL LYMPHOMA ATLAS OF TUMOR MICROENVIRONMENT FOR PREDICTIVE MODELING
Mattie, M., Perbost, R., Turcan, S., Danan, C., Locke, F., Neelapu, S., … Galon, J. (2022). MULTIOMICS AND MULTIMODAL ANALYSIS APPROACH TO CONSTRUCT A DIFFUSE LARGE B CELL LYMPHOMA ATLAS OF TUMOR MICROENVIRONMENT FOR PREDICTIVE MODELING. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.

BASECAMP-1: LEVERAGING HLA LOSS OF HETEROZYGOSITY IN SOLID TUMORS BY NGS TO IDENTIFY PATIENTS WITH RELAPSED SOLID TUMORS FOR FUTURE CEA AND MSLN LOGIC-GATED TMOD (TM) CAR T-CELL THERAPY
Simeone, D., Morelli, M. P., Hecht, J. R., Patel, S., Fakih, M., Kirtane, K., … Molina, J. (2022). BASECAMP-1: LEVERAGING HLA LOSS OF HETEROZYGOSITY IN SOLID TUMORS BY NGS TO IDENTIFY PATIENTS WITH RELAPSED SOLID TUMORS FOR FUTURE CEA AND MSLN LOGIC-GATED TMOD (TM) CAR T-CELL THERAPY. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.

Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma.
Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., … Locke, F. L. (2023). Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma. Blood Advances.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A. A., Ghobadi, A., … Locke, F. L. (2023). Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. The New England Journal of Medicine.

Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma.
Hamilton, M. P., & Miklos, D. B. (2023). Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma. Hematology/Oncology Clinics of North America.

Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., … Natkunam, Y. (2023). Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 100256.

Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11.
Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., … Reshef, R. (2023). Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
Westin, J., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., … Locke, F. L. (2023). Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.

Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection
Ananth, S., Su, Y.-J., Hamilton, M. P., Agarwal, N., Weng, W.-K., Dahiya, S., … Frank, M. J. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. BLOOD. AMER SOC HEMATOLOGY.

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial
Cutler, C., Kim, H. T., El Banna, H., Halloran, E., Matozel, E., Ho, V., … Ritz, J. (2023). Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial. BLOOD. AMER SOC HEMATOLOGY.

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
Spiegel, J. Y., Jain, M. D., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., … Dahiya, S. (2023). Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. BLOOD. AMER SOC HEMATOLOGY.

Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab.
Kennedy, V. E., Sahaf, B., Wu, F., Ehlinger, Z. J., Arai, S., & Miklos, D. B. (2024). Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab. Transplantation and Cellular Therapy.

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances.

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning, M. A., Wang, H.-L. L., Hu, Z.-H. H., Locke, F. L., Siddiqi, T., Jacobson, C. A., … Pasquini, M. C. (2024). Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. American Journal of Hematology.

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., … Miklos, D. B. (2024). Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. The New England Journal of Medicine, 390(22), 2047–2060.

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England).

Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma.
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., … Miklos, D. B. (2024). Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma. Transplantation and Cellular Therapy.

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

A Phase 1 Study of ADI-001 in B Cell Malignancies

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

900 Blake Wilbur Drive, 2nd Floor

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(39 Ratings)

Overall Rating

4.8/5

View Ratings by Category

4.8/5

Friendliness

4.9/5

Explanations

4.9/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

4.8/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(99 reviews)

He's great. I feel very grateful to be under his care.

Jun 2024

•

Verified SHC Patient

He is an excellent Doctor

May 2024

•

Verified SHC Patient

Knowledgable, helpful and takes action to continue the level of excellence that Stanford has been known for.

May 2024

•

Verified SHC Patient

I feel confident with Dr. Miklos and trust his judgment.

Apr 2024

•

Verified SHC Patient

I appreciate my Dr and everything heâ€™s doing for me. Heâ€™s like an angel watching over my stem cell progress

Jan 2024

•

Verified SHC Patient

Very knowledgeable, very detailed oriented, very concerned that a proper course of action be taken.

Jan 2024

•

Verified SHC Patient

His excellent and professional performance made me feel I can beat any sickness

Jan 2024

•

Verified SHC Patient

Dr Miklos is a great doctor he listens to me and explains things clearly I am very thankful for his care

Dec 2023

•

Verified SHC Patient

Dr. Miklos is a very competent caring physician. I appreciate his expertise.

Oct 2023

•

Verified SHC Patient

He is so knowledgeable and compassionate we are glad he is our Dr

Aug 2023

•

Verified SHC Patient

I truly appreciate his experience in treating My type of cancer. Heâ€™s a wealth of knowledge and always gives me the latest ideas in treatment.

Aug 2023

•

Verified SHC Patient

Heâ€™s an excellent doctor and Always to the point of your visit.

Aug 2023

•

Verified SHC Patient

Thank you Dr Miklos for taking care of me very well!

Jun 2023

•

Verified SHC Patient

Very good

May 2023

•

Verified SHC Patient

I found the care I received from de Miklos and rest of very good and helpful, thankful for care

Apr 2023

•

Verified SHC Patient

Has provided great service to me; perhaps saving my life.

Apr 2023

•

Verified SHC Patient

Outstanding physician.

Apr 2023

•

Verified SHC Patient

He is the greatest, as a medical doctor and as a positive person to go through cancer with. Love him!

Feb 2023

•

Verified SHC Patient

Dr David Miklos has provided me all the health care that I need right from the start. I trust him. He listens and answers all my questions, and i am always part of the treatment plan. He always make sure that I understand all his instructions and answers any question that I might have. He make sure that I am always in the best of health. His whole team has been great and I appreciate everything that they have done and have been doing to make me well. I can't thank them enough.

Feb 2023

•

Verified SHC Patient

He is an very professional doctor and easy to talk to

Jan 2023

•

Verified SHC Patient

Very good

Dec 2022

•

Verified SHC Patient

Doctor was very knowledgeable and gave us a lot of time to explain things.

Dec 2022

•

Verified SHC Patient

He went out of his way to deliver ClonoSeq kit to me while I was in the hospital. The Director of BMT and CAR-T did that!

Dec 2022

•

Verified SHC Patient

Dr Miklos and his staff are the best .

Nov 2022

•

Verified SHC Patient

Explained things well

Nov 2022

•

Verified SHC Patient

Your Staff is outstanding

Oct 2022

•

Verified SHC Patient

Listened well to my questions and concerns and provided options.

Sep 2022

•

Verified SHC Patient

GREAT STAFF

Aug 2022

•

Verified SHC Patient

Take a good care of the patients.

Aug 2022

•

Verified SHC Patient

Dr miklos said the bmt saved my life,you can't say anything wrong with that

Aug 2022

•

Verified SHC Patient

Wonderful Doctor

Jul 2022

•

Verified SHC Patient

David is a great Dr

Jul 2022

•

Verified SHC Patient

Explanations well done

Jun 2022

•

Verified SHC Patient

Empathetic, knowledgeable and covers everything. I couldn't be more pleased.

Jun 2022

•

Verified SHC Patient

Dr. Miklos is an exceptional physician and I am truly greatful for his time and expert care.

May 2022

•

Verified SHC Patient

Very professional and concerned. Exceptional listening efforts

May 2022

•

Verified SHC Patient

Excellent

May 2022

•

Verified SHC Patient

He is an excellent doctor and very knowledgeable and thorough.

Feb 2022

•

Verified SHC Patient

Thank you!

Feb 2022

•

Verified SHC Patient

Very good

Feb 2022

•

Verified SHC Patient

Dr. Miklos was about the only person left in the clinic that evening when we did our video visit. It was late, but he took the time to address the issues regarding my post CAR T and he answered my questions completely. His concern and dedication comes through, whether virtual or actual visits. The virtual visit is necessary for me at times due to distance and of course Covid. Dr. Miklos is an amazing physician and my family and I couldn't be happier in having him as my hematologist.

Jan 2022

•

Verified SHC Patient

He's been my BMT doctor for 15 years, and he is caring, compassionate and professional.

Jan 2022

•

Verified SHC Patient

I think he is a great doctor. He is accommodating and a pleasure to talk to.

Dec 2021

•

Verified SHC Patient

He's still the best.

Dec 2021

•

Verified SHC Patient

This Doctor is the best in my opinion and do recommend him to anyone who is in need of his specialty. I am constantly telling my family, friends and neighbors about how professional and caring he is along with his specialty skills.

Oct 2021

•

Verified SHC Patient

Great doctor and always tries to answer all of my questions.

Oct 2021

•

Verified SHC Patient

I am very thankful with the care I received from him

Sep 2021

•

Verified SHC Patient

I have the highest regard for him and his staff. I absolutely trust and respect him as a doctor and as a human being.

Sep 2021

•

Verified SHC Patient

Dr.Miklos and the BMT team saved my life,you can't imagine what that is like

Aug 2021

•

Verified SHC Patient

He's great, and so is his team!! Explains things well and is honest about your condition. He is also brilliant and straight-forward and is easy to talk to. Glad I found him!

Jun 2021

•

Verified SHC Patient

An excellent physician, very caring, easy to talk to and provided me with answers to all my questions.

May 2021

•

Verified SHC Patient

Dr miklos is great he is very kind and very helpful

Apr 2021

•

Verified SHC Patient

Dr. Miklos is very smart and caring he always can answer all of our questions! Iâ€™m so very grateful to have met him. Dr. Miklos thank you for helping me through my journey ! I do wish he was my primary care dr. as well.. we found out 11:00 pm on November 4th, 2014 in a Kaiserâ€™s emergency room about my wifeâ€™s leukemia. Thatâ€™s when our nightmare began. The next two years we went through treatments that helped for awhile but wast sustainable. Thatâ€™s when we were introduced to Stanford Health Care and Dr. Miklos. When I speak of Stanford my statement is always the same. Itâ€™s Stanford and then everybody else. You should be very proud for the work you do. When I speak of Dr Miklos I always say he is the nearest thing to god I will ever see. Thank god he put Dr Miklos in our lives.

Apr 2021

•

Verified SHC Patient

Dr. Miklos & Janette Kimes were wonderful to have on "my" team. EXCELLENT!

Feb 2021

•

Verified SHC Patient

5+ years of care very honored to call David my dr.

Dec 2020

•

Verified SHC Patient

We felt that the whole process and decision for treatment was thoroughly explained using imaging and diagrams.

Sep 2020

•

Verified SHC Patient

Dr. Miklos spent time explaining & answering my questions. Did not feel rushed, Dr. Miklos took time to explain... excellent!!!

Jun 2020

•

Verified SHC Patient

Dr. Miklos was great! Could not yell it louder if I was Tony the Tiger.

Feb 2020

•

Verified SHC Patient

Dr. Miklos and team are AMAZING.

Dec 2019

•

Verified SHC Patient

I have told everyone who will listen about the excellent care, concern, and warmth of the staff at Stanford.

Dec 2019

•

Verified SHC Patient

An excellent experience! This was a visit to discuss treatments for serious disease. Dr. Miklos seems like an excellent clinician AND a researcher. It was like having an oncologist in the family!

Nov 2019

•

Verified SHC Patient

Dr. Miklos and his physician assistant always gave me the best care possible.

Sep 2019

•

Verified SHC Patient

Good because they provided very good time.

Sep 2019

•

Verified SHC Patient

Dr. Miklos is the best. I am alive because of him and the treatment at Stanford.

Jun 2019

•

Verified SHC Patient

The doctors & support staff were very supportive and positive to addressing my problem (cancer) and my recovery.

May 2019

•

Verified SHC Patient

I was very impressed.

May 2019

•

Verified SHC Patient

Since this was a trial, the staff was very open & honest regarding expected results.

Mar 2019

•

Verified SHC Patient

The staff's care of my treatment was very good, especially their positive attitude for my recovery.

Jan 2019

•

Verified SHC Patient

Dr. Miklos and his fellow, Jay Spiegal, are extremely knowledgeable, regarding my situation - answer all questions so that I could understand and are always caring and helpful.

Dec 2018

•

Verified SHC Patient

All are friendly.

Apr 2018

•

Verified SHC Patient

All good & excellent. Excellent dr.

Apr 2018

•

Verified SHC Patient

Dr. Miklos has the best bedside manor. He makes us feel so special.

Apr 2018

•

Verified SHC Patient

Dr. Miklos is outstanding. I feel confident I am getting to best (latest) care available.

Oct 2017

•

Verified SHC Patient

Very professional.

Aug 2017

•

Verified SHC Patient

An amazing doctor, totally feel taken care of, when under his care.

Jul 2017

•

Verified SHC Patient

Dr. Miklos is exceptional.

May 2017

•

Verified SHC Patient

Dr. Miklos good job he cares so much about his treatment for you and how you are doing.

Feb 2017

•

Verified SHC Patient

The doctor spent a lot of time with us explaining my care, his team also spent a lot of time with us explaining treatment.

Feb 2017

•

Verified SHC Patient

I fully trust Dr. Miklos with all my medical concerns. He's very caring & welcomed me & my family well. His nursing assistant is also great! Her name is Sandy Burgess & she always took care of all my concerns.

Jan 2017

•

Verified SHC Patient

Dr. Miklos is very knowledgable & empathetic. Always available & responsive.

Dec 2016

•

Verified SHC Patient

Huge fan of Dr Miklos!

Dec 2016

•

Verified SHC Patient

Dr. Mikios is a wonderful doctor and a kind man.

Dec 2016

•

Verified SHC Patient

Excellent.

Sep 2016

•

Verified SHC Patient

Dr. Miklos is a star doctor. He genuinely cares about me and spends generous amount of time with me and my family. I got educated on my illness and I am very thankful to Dr. Miklos and his team.

Aug 2016

•

Verified SHC Patient

Miklos provided a thorough amount of hand written info - But I was overwhelmed by the depth and technical aspects of what he described.

Aug 2016

•

Verified SHC Patient

Dr. Miklos is the best! I feel very grateful to have him as my doctor!

May 2016

•

Verified SHC Patient

Dr. Mikios is my hero. I thank him for taking me through the transplant and the following care.

May 2016

•

Verified SHC Patient

I have just recently recommended Dr. Miklos.

Nov 2015

•

Verified SHC Patient

They were great. Spoke clearly and spoke my language. They even made a visual to clarify it.

Aug 2015

•

Verified SHC Patient

Dr. Miklos spent a lot of time with me and answered all my questions.

May 2015

•

Verified SHC Patient

Dr. Miklos & the entire team was amazing the total care I received was truly wonderful.

May 2015

•

Verified SHC Patient

Amazing care provided by Dr. Miklos. Lots of good information.

May 2015

•

Verified SHC Patient

Dr. Miklos is wonderful, approachable and thorough.

Apr 2015

•

Verified SHC Patient

One time I had a concern which really scared me when the dr. just say it is what it is and I felt like I'm just a number in a study and I just wondered how serious my illness (life) is in this study or if I'm just a number.

Mar 2015

•

Verified SHC Patient

Dr. Miklos is amazing.

Feb 2015

•

Verified SHC Patient

Good.

Oct 2014

•

Verified SHC Patient

Dr. Miklos always answers any questions I have and has always given me the best care.

Sep 2014

•

Verified SHC Patient

Dr. Miklos from thy 1st time I met him to my last visit I could have a more understanding, knowledgeable doctor ever. He is outstanding.

Apr 2014

•

Verified SHC Patient

Dr. Miklos saved my life. Because of him I get to watch my daughter grow.

Mar 2014

•

Verified SHC Patient

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

David Miklos

Blood and marrow transplant specialist, Hematologist, Medical oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(99 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

David Miklos

Blood and marrow transplant specialist, Hematologist, Medical oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(99 reviews)

Referring Physicians

PHYSICIAN HELPLINE